Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting.

Wang, Ji-Nuo; Gu, Tianning; Hu, Yongxian; Huang, He

Wang, Ji-Nuo; Gu, Tianning; Hu, Yongxian; Huang, He.

Afiliación

Wang JN; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, 310003, Zhejiang, China.
Gu T; Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China.
Hu Y; Institute of Hematology, Zhejiang University, Hangzhou, China.
Huang H; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China.

Exp Hematol Oncol ; 11(1): 61, 2022 Sep 24.

Article en En | MEDLINE | ID: mdl-36153595

Palabras clave

Cellular immunotherapy; Chimeric antigen receptor (CAR); Hematological malignancies; Induced pluripotent stem cell (iPSC); The 2021 ASH annual meeting

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Exp Hematol Oncol Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Exp Hematol Oncol Año: 2022 Tipo del documento: Article País de afiliación: China